CMRX Projected Dividend Yield
Chimerix Inc. ( NASDAQ : CMRX )Chimerix, Inc. is a biotechnology company. Co. is focused on developing medicines that address unmet medical needs. Co.'s product Imipridones is a cancer therapy that provides ONC201, which is in clinical-stage development for H3 K27M-mutant glioma as its lead indication. In addition, imipridone ONC206 is in dose-escalating clinical trials. Imipridones target specific G protein-coupled receptors (GPCRs) and mitochondrial caseinolytic protease P (ClpP), resulting in cancer cell death. Co.'s product Imipridone chemical scaffold provides an opportunity to target GPCRs and ClpP with differential specificity and function. 20 YEAR PERFORMANCE RESULTS |
CMRX Dividend History Detail CMRX Dividend News CMRX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |